SYSTIMMUNE


Associated tags: Spacecraft, Drug development, ADC, Patient, Breast cancer, Pharmaceutical industry, NSCLC, Oncology, IND, Lung cancer, Medical imaging, ASCO, ESMO, Research, Safety, FDA, CMO, EGFR, Investigational New Drug, HER2, Trial of the century

Locations: WASHINGTON, CHINA, BOSTON, UNITED STATES, NY, EUROPE, WA

SystImmune, Inc. Appoints Dr. Jie D'Elia as Chief Executive Officer

Retrieved on: 
Monday, April 22, 2024
D'Elía, University, Cancer, Hematology, Virology, Baxter International, Business, Growth, AstraZeneca, Simcere Pharmaceutical, Therapy, Senior, Patient, Bristol Myers Squibb, Fibrosis, College, Columbia Business School, MBA, BMS, Boston Consulting Group, Jie, Drug development, Spacecraft, Moses Austin, Strategic planning, Fine chemical

Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation.

Key Points: 
  • Dr. D'Elia's extensive experience in drug development, strategic planning, and business development is poised to propel SystImmune into its next phase of growth and innovation.
  • I look forward to working with her as we steer SystImmune towards new horizons of development and success."
  • Its highly differentiated platforms discovering bi-specific and multi-specific antibodies and ADCs stand out as a testament to its innovative capabilities.
  • Dr. D'Elia received her Ph.D. from the College of Pharmacy at the University of Texas at Austin and her MBA from Columbia Business School.

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

Retrieved on: 
Monday, December 11, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Bristol Myers Squibb, NYSE, Safety, ADC, Breast cancer, ESMO, Patient, ASCO, BMY, Lung cancer, MD, Drug development, NSCLC, Pharmaceutical industry

SystImmune, a clinical-stage biopharmaceutical company, and Bristol Myers Squibb (NYSE: BMY) today announced an exclusive license and collaboration agreement for SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).

Key Points: 
  • SystImmune, a clinical-stage biopharmaceutical company, and Bristol Myers Squibb (NYSE: BMY) today announced an exclusive license and collaboration agreement for SystImmune’s BL-B01D1, a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC).
  • Bristol Myers Squibb will assume sole responsibility for development and commercialization in the rest of the world.
  • “We have long admired Bristol Myers Squibb’s global clinical development and commercialization capabilities in oncology, and this strategic collaboration is an exciting step forward in delivering potential antitumor medicines to patients worldwide.
  • Through its affiliates, SystImmune will retain exclusive development and commercialization rights in Mainland China, where Bristol Myers Squibb will receive a royalty on net sales.

SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2024 San Antonio Breast Cancer Conference and US Clinical Trial Developments

Retrieved on: 
Tuesday, December 5, 2023
Safety, Food, Spacecraft, ILD, IND, ADC, Breast cancer, Patient, FDA, Investigational New Drug, HER2, Trial of the century, Cancer, TNBC, Optimism, Pharmaceutical industry, Medical imaging

We look forward to collaborating with our clinical partners, trial treatment centers, and global regulatory agencies to contribute meaningfully to the ongoing evolution of cancer treatment."

Key Points: 
  • We look forward to collaborating with our clinical partners, trial treatment centers, and global regulatory agencies to contribute meaningfully to the ongoing evolution of cancer treatment."
  • For more information visit poster: PS08-07 2024 San Antonio Breast Cancer conference.
  • For more information visit poster: PO2-04-03 2024 San Antonio Breast Cancer conference.
  • "As the clinical development of BL-M07D1 and BL-B01D1 progress, we're closer to assessing our potential to offer therapeutic pathways for patients diagnosed with breast cancer."

SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023

Retrieved on: 
Saturday, October 21, 2023
ESMO, HER2, Congress, European Society for Medical Oncology, Candidate, American Society of Clinical Oncology, Society, Clinical, ADC, HER3, Spacecraft, Oncology, CMO, Patient, ASCO, EGFR, Vaccine, Nursing

The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.

Key Points: 
  • The event is scheduled to take place from October 20th to 24th in Madrid, Spain, where new clinical findings will be unveiled from trials involving BL-B01D1 and BL-M07D1.
  • The expanded results from these clinical trials of BL-B01D1 will include data from patients with several solid tumor types in advanced stages and having multiple cycles of prior therapies.
  • The data presented at ESMO builds on previously reported clinical data at the American Society of Clinical Oncology (ASCO), and recent recognition for BL-B01D1 conferred by industry experts at the 14th Annual World ADC meeting in San Diego who recognized SystImmune's BL-B01D1 as a "Runner-Up" in the award category of "Most Promising Clinical Candidate".
  • Presentations at the ESMO congress include:

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-B01D1, a Bi-specific Antibody Drug Conjugate Targeting EGFR and HER3, Enabling Initiation of Phase 1 Clinical Trials for the Treatment of Metastatic or Unresectable Non-Small Cell Lung Can

Retrieved on: 
Sunday, July 2, 2023
Trial of the century, ADC, Investigational New Drug, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NSCLC, Patient, Food, Non-small-cell lung cancer, Pharmaceutical industry, IND

This milestone paves the way for Phase 1 clinical trials of BL-B01D1 in subjects with metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) in the United States.

Key Points: 
  • This milestone paves the way for Phase 1 clinical trials of BL-B01D1 in subjects with metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) in the United States.
  • The clearance of this IND application marks a significant milestone for SystImmune as the company continues to advance its pipeline of novel therapeutic candidates into clinical development.
  • Together, with all our clinical partners, trial treatment centers, and global regulatory agencies, we hope to provide significant and global contributions to the cancer treatment landscape."
  • "We are excited to receive FDA clearances for the IND application of Bl-B01D1, the first-in-class bi-specific ADC.

Leaders in Breast and Lung Cancer treatment join SystImmune Inc's Clinical Science Advisory Committee

Retrieved on: 
Wednesday, April 26, 2023
IDeA Networks of Biomedical Research Excellence, TNBC, Memorial Sloan Kettering Cancer Center, Triple-negative breast cancer, Therapy, SPORE, CDK, Cancer and Leukemia Group B, Belfer Center for Science and International Affairs, Survival, Cancer, Lung cancer, Woman, MMSC, Research, NSCLC, CMO, CALGB, Immunotherapy, Biomarker, Associate, Oncology, Harvard Medical School, CSAC, Patient, UCSF, Breast cancer, Division, Susan, EGFR, MSK, Biology, ADC, Haematopoietic system, Antibody-drug conjugate, George M. Low Center for Industrial Innovation, Disease, Dana–Farber Cancer Institute, Medical device, Birth control, Medical imaging, Sacituzumab govitecan, Medicine

Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.

Key Points: 
  • Dr. Rugo and Dr. Tolaney bring more than 40 years combined of breast cancer clinical experience in early oncology research and global drug development.
  • They have led high-profile clinical programs, including the development of Trodelvy (sacituzumab govitecan-hziy), the most recent drug approved for the treatment of triple-negative breast cancer (TNBC).
  • Their expertise will guide SystImmune in the advancement of its ADC pipeline into breast cancer.
  • Dr. Rugo is the director of UCSF's breast cancer clinical trials program and the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late-stage breast cancer.